[ODP5C] c. 感染予防（ワクチン接種とその他の感染予防法）

[ODP-097] 抗血清およびモノクローナル抗体によるマウス胃内ピロリ菌定着阻害効果

○Subsomwong Phawinee^1,2，大坪 亮太^1,3，三室 仁美¹ (¹阪大・微研・感染微生物，²弘前大・院医・感染生体防御，³ 富山県立大・くすりのサテライトラボ・薬総研)

Helicobacter pylori is a Gram-negative bacterium that cause gastritis, ulcer and gastric cancer, and they persist in 50% of world populations stomach. The increased drug resistance to H. pylori made treatment harder. This study used a monoclonal antibody (mAb) to treat H. pylori infections. The C57BL/6J mice were infected with H. pylori PMSS1 strain for five weeks. The H. pylori specific-Igs were detected from the serum by ELISA assay, the H. pylori colonized in the stomach was counted and the B-cell population was analyzed by flow cytometry. The mAbs were generated by mice spleen infected with H. pylori using the hybridoma technique, the positive clones were tested for anti-colonization activities. H. pylori persisted in the stomach and induced high H. pylori-specific IgG titer at 4-5 weeks post-infection (WPI). The protective H. pylori colonization effect by the H. pylori infected mice serum was found at 5 WPI. We got two positive IgG and IgG2c-producing clones. The mAb from clone 1 bound with H. pylori cells and had the ability to control the infection in mice’s stomach. The humoral antibody and mAb from the infected mice have the prospects to reduce H. pylori. To develop passive antibody therapy in H. pylori infected patients, the epitope of H. pylori antigen and the variable region of mAb specific to H. pylori have to be characteristic.